Postherpetic Neuralgia

Categories: Neuronal diseases, Skin diseases

Aliases & Classifications for Postherpetic Neuralgia

MalaCards integrated aliases for Postherpetic Neuralgia:

Name: Postherpetic Neuralgia 53 70


External Ids:

UMLS 70 C0032768

Summaries for Postherpetic Neuralgia

NINDS : 53 Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain (which can be severe), or sometimes numbness or itch,generally on one side of the body. After several days or a week, a rash of fluid-filled blisters, similar to chickenpox, appears in one area on one side of the body. Shingles pain can be mild or intense.  Some people have mostly itching; some feel pain from the gentlest touch or breeze.  The most common location for shingles is a band, called a dermatome, spanning one side of the trunk around the waistline. Anyone who has had chickenpox is at risk for shingles.  Scientists think that some of the virus particles from the original exposure to the varicella-zoster virus,leave the skin blisters and move into the nervous system.  When the varicella-zoster virus reactivates, the virus moves back down the long nerve fibers that extend from the sensory cell bodies to the skin.  The viruses multiply, the tell-tale rash erupts, and the person now has shingles.

MalaCards based summary : Postherpetic Neuralgia is related to herpes zoster and uveitis, and has symptoms including sciatica and neuralgia. An important gene associated with Postherpetic Neuralgia is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Actin Nucleation by ARP-WASP Complex and Measles. The drugs Etoricoxib and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, dorsal root ganglion and heart, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Postherpetic neuralgia (PHN) is neuropathic pain that occurs due to damage to a peripheral nerve caused... more...

Related Diseases for Postherpetic Neuralgia

Diseases related to Postherpetic Neuralgia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
# Related Disease Score Top Affiliating Genes
1 herpes zoster 31.9 HLA-DRB1 HLA-B HLA-A
2 uveitis 29.9 HLA-B HLA-A
3 graft-versus-host disease 29.3 HLA-DRB1 HLA-B HLA-A
4 autoimmune disease 29.2 HLA-DRB1 HLA-B HLA-A
5 exanthem 11.0
6 chickenpox 11.0
7 chronic pain 10.7
8 neuropathy 10.6
9 diabetic neuropathy 10.6
10 peripheral nervous system disease 10.5
11 pain agnosia 10.5
12 trigeminal neuralgia 10.4
13 herpes simplex 10.4
14 paresthesia 10.4
15 polyneuropathy 10.3
16 peptic ulcer disease 10.3
17 cytokine deficiency 10.3
18 herpes zoster ophthalmicus 10.3
19 anxiety 10.3
20 neuromuscular disease 10.3
21 myelitis 10.2
22 fibromyalgia 10.2
23 depression 10.2
24 ataxia and polyneuropathy, adult-onset 10.1
25 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1
26 osteonecrosis 10.1
27 nasopharyngitis 10.1
28 diabetic polyneuropathy 10.1
29 personality disorder 10.1
30 mental depression 10.1
31 neuritis 10.1
32 constipation 10.1
33 complex regional pain syndrome 10.1
34 skin disease 10.1
35 dystonia 10.1
36 back pain 10.1
37 headache 10.1
38 spasticity 10.1
39 spinal cord injury 10.1
40 tropical spastic paraparesis 10.0 HLA-B HLA-A
41 spastic paraparesis 10.0 HLA-B HLA-A
42 frontal fibrosing alopecia 10.0 HLA-B HLA-A
43 atrial standstill 1 10.0
44 carpal tunnel syndrome 10.0
45 discrimination, two-point, reduction in 10.0
46 erythermalgia, primary 10.0
47 hemifacial spasm, familial 10.0
48 leukemia, chronic lymphocytic 10.0
49 migraine with or without aura 1 10.0
50 greig cephalopolysyndactyly syndrome 10.0

Graphical network of the top 20 diseases related to Postherpetic Neuralgia:

Diseases related to Postherpetic Neuralgia

Symptoms & Phenotypes for Postherpetic Neuralgia

UMLS symptoms related to Postherpetic Neuralgia:

sciatica; neuralgia

GenomeRNAi Phenotypes related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 10.33 HLA-A HLA-B
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 10.33 HLA-A HLA-B
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 10.33 HLA-A HLA-B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 10.33 HLA-A HLA-B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.33 P2RX7
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 10.33 HLA-A HLA-B
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 10.33 HLA-A HLA-B
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.33 P2RX7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 10.33 HLA-A HLA-B
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 10.33 P2RX7

Drugs & Therapeutics for Postherpetic Neuralgia

Drugs for Postherpetic Neuralgia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Acetaminophen Approved Phase 4 103-90-2 1983
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Esketamine Approved, Investigational Phase 4 33643-46-8
Amitriptyline Approved Phase 4 50-48-6 2160
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
16 Sodium Channel Blockers Phase 4
17 Diuretics, Potassium Sparing Phase 4
18 Antirheumatic Agents Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Cyclooxygenase Inhibitors Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 diuretics Phase 4
23 Neurotransmitter Agents Phase 4
24 Excitatory Amino Acid Antagonists Phase 4
25 Sodium Potassium Chloride Symporter Inhibitors Phase 4
26 Cyclooxygenase 2 Inhibitors Phase 4
27 abobotulinumtoxinA Phase 4
28 Cholinergic Agents Phase 4
29 Botulinum Toxins, Type A Phase 4
30 Botulinum Toxins Phase 4
31 Anesthetics, Local Phase 4
32 Anti-Inflammatory Agents Phase 4
33 Gastrointestinal Agents Phase 4
34 Antiemetics Phase 4
35 Hormone Antagonists Phase 4
36 glucocorticoids Phase 4
37 Antineoplastic Agents, Hormonal Phase 4
38 Amitriptyline, perphenazine drug combination Phase 4
39 Analgesics Phase 4
40 Psychotropic Drugs Phase 4
41 Anti-Anxiety Agents Phase 4
42 Anticonvulsants Phase 4
43 Hormones Phase 4
44 calcium channel blockers Phase 4
45 Calcium, Dietary Phase 4
Calcium Nutraceutical Phase 4 7440-70-2 271
Capsaicin Approved Phase 3 404-86-4 1548943
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
Hydrocodone Approved, Illicit, Investigational Phase 3 125-29-1 5284569
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 3 14838-15-4 26934

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
2 A Prospective, Randomized Study Evaluating the Efficacy and Safety of Early Diuresis Following Colorectal Surgery Completed NCT02351934 Phase 4 Furosemide;Celecoxib;Gabapentin
3 An 8-week Randomized, Double Blind, Multi-center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin ( 300mg/Day ) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Postherpetic Neuralgia ( Phn ) Completed NCT01455428 Phase 4 Lyrica (pregabalin);Placebo
4 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
5 Randomized Placebo-Controlled Study of the Efficacy of Botulinum Toxin Type A (Botox) in Spontaneous Pain and Allodynia Related to Traumatic Nerve Injury or Postherpetic Neuralgia Completed NCT00527202 Phase 4 botulinum toxin A and saline
6 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
7 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
8 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
9 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
10 The Study on the Esketamine in the Treatment of Postherpetic Neuralgia Recruiting NCT04664530 Phase 4 esketamine;Saline
11 The Effect of Epidural Steroid Use on Pain Relief in Patients With Continuous Epidural Nerve Block in Postherpetic Neuralgia Patients. Recruiting NCT03995563 Phase 4 Dexamethasone;Ropivacaine
12 A Phase 4 Multicenter, Open-Label, Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia Terminated NCT01603394 Phase 4 pregabalin
13 Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia -A Multicenter,Randomized, Double-blind, Placebo-controlled Trial Unknown status NCT02868801 Phase 3 Placebo;Pregabalin SR tablet 165mg/day;Pregabalin SR tablet 330mg/day;Pregabalin SR tablet 660mg/day
14 Prevention Effect of Pregabalin on Postherpetic Neuralgia: A Multicenter, Randomized, Double-blind, Controlled Trial Unknown status NCT03186443 Phase 3 Pregabalin;Gabapentin
15 A 12-Month, Open-Label Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours in Patients Who Require Opioid Treatment for an Extended Period of Time Completed NCT01223365 Phase 3 Hydrocodone ER
16 A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00300222 Phase 3 NGX-4010
17 A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00115310 Phase 3 NGX-4010
18 A 12-Week Open-Label Study With 3 Within-Patient Double-Blind Placebo-Controlled Periods to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain Completed NCT00343733 Phase 3 OraVescent Fentanyl
19 An Open-label, Multicenter, Multiple-dose, Phase III Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia Completed NCT03765697 Phase 3 Lidocaine 5% medicated plaster
20 A Double-blind, Multicentre, Multiple-dose, Enriched Enrolment, Randomized-withdrawal, Parallel-group Phase III Study With Lido-Patch and Corresponding Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN) Completed NCT03745404 Phase 3 Lidocaine 5% medicated Plaster;Placebo Plaster
21 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia Completed NCT00636636 Phase 3 Gabapentin Extended Release tablets;Placebo
22 A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224) Completed NCT01270828 Phase 3 Pregabalin;placebo
23 A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo Completed NCT00377598 Phase 2, Phase 3 TAK-583;TAK-583;TAK-583;TAK-583;Placebo
24 A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In The Treatment Of Postherpetic Neuralgia Completed NCT00424372 Phase 3 pregabalin
25 An Open-Label Extension Safety and Efficacy Study of Pregabalin in Patients With Postherpetic Neuralgia Completed NCT00150436 Phase 3 Pregabalin
26 A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00061776 Phase 2, Phase 3 Capsaicin Dermal Patch
27 Safety and Efficacy of Lidocaine 5% Medicated Plaster in Comparison to Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain. Completed NCT00414349 Phase 3 Topical analgesic;oral intake;Topical analgesic
28 A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin In The Treatment Of Postherpetic Neuralgia Completed NCT00394901 Phase 3 Placebo;Pregabalin;Pregabalin;Pregabalin
29 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia Completed NCT00335933 Phase 3 Gabapentin extended-release tablets
30 A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00068081 Phase 3 Capsaicin Dermal Patch
31 Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia Completed NCT00004390 Phase 3 desipramine;methadone;morphine;nortriptyline
32 A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
33 Phase 2/3 Multi-Center, Double-Blind, Controlled Trial Comparing Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir, and Combination Topical ARYS-01 Cream /Oral Valaciclovir for Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age or Older Unknown status NCT00652184 Phase 2 ARYS-01 (sorivudine) cream 3% or placebo cream;placebo;valaciclovir
34 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia Unknown status NCT00813826 Phase 2 SLC022;Placebo
35 Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain: Randomized, Controlled, Comparative Study Unknown status NCT02597257 Phase 2 Lidocaine HCl;Normal saline
36 A Randomized, Double-Blind, Crossover Study Comparing Pliaglis™ (Lidocaine and Tetracaine) Cream 7%/7% to Placebo Cream When Applied for 60 Minutes in the Treatment of Patients With Postherpetic Neuralgia Completed NCT00609323 Phase 2 lidocaine and tetracaine cream 7%/7%;Placebo
37 A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Multicenter, Parallel Group Study to Evaluate the Safety and Analgesic Activity of ATx08-001 When Administered to Subjects With Postherpetic Neuralgia Completed NCT01318226 Phase 2 ATx08-001;Placebo
38 A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or 20% w/w) in Subjects With Postherpetic Neuralgia (PHN) Completed NCT01228838 Phase 2 NGX-1998;Placebo Liquid
39 A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia Completed NCT01129531 Phase 2 AGN-214868;Placebo to AGN-214868
40 Mannitol Cream in the Treatment of Post-herpeticNeuralgia;a Randomized Placebo-Controlled Crossover Pilot Study Completed NCT02484170 Phase 1, Phase 2 Mannitol cream;Placebo
41 The Clinical Trial for Evaluation of Efficacy and Safety of DWP05195 in Postherpetic Neuralgia: Double-blind, Placebo-controlled, Randomized, Multi-center, Exploratory Clinical Trial Completed NCT01557010 Phase 2 DWP05195;DWP05195;DWP05195;Control
42 Phase II Study of KHK6188 (A Placebo-controlled, Double Blind, Crossover Study of KHK6188 in Postherpetic Neuralgia) Completed NCT01544296 Phase 2 KHK6188;Placebo
43 A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN). Completed NCT00861068 Phase 2 SPM927/Lacosamide
44 A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) Completed NCT01688947 Phase 2 V116517 50-mg tablets;V116517 30-mg tablets;Pregabalin capsules;Placebo
45 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group With a Crossover Confirmation Period Study of RWJ-333369 for the Treatment of Postherpetic Neuralgia. Completed NCT00492323 Phase 2 placebo;carisbamate
46 Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia Completed NCT01124617 Phase 2 Tapentadol;Placebo
47 A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Completed NCT00576108 Phase 2 KD7040 Topical Gel;Placebo gel
48 An Open-Label Study Of The Use Of Topical Lidocaine (2.5%)/Prilocaine (2.5%) Cream As Pre-Treatment For NGX-4010 In Subjects With Postherpetic Neuralgia (PHN) Completed NCT00916942 Phase 2 capsaicin 8%;Lidocaine (2.5%)/Prilocaine (2.5%) Cream
49 A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia Completed NCT01106716 Phase 2 Placebo;KAI-1678;Lidocaine
50 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Systemic Exposure of Topical XPF-002 in Subjects With Postherpetic Neuralgia Completed NCT01195636 Phase 2 XPF-002;Placebo

Search NIH Clinical Center for Postherpetic Neuralgia

Genetic Tests for Postherpetic Neuralgia

Anatomical Context for Postherpetic Neuralgia

MalaCards organs/tissues related to Postherpetic Neuralgia:

Spinal Cord, Dorsal Root Ganglion, Heart, Brain, Eye, Skin, T Cells

Publications for Postherpetic Neuralgia

Articles related to Postherpetic Neuralgia:

(show top 50) (show all 2049)
# Title Authors PMID Year
Intravenous patient-controlled analgesia hydromorphone combined with pregabalin for the treatment of postherpetic neuralgia: a multicenter, randomized controlled study. 61
33785673 2021
Serum interleukin-10 level increases in patients with severe signs or symptoms of herpes zoster and predicts the duration of neuralgia. 61
33609414 2021
Lumbar Sympathetic Block for Postherpetic Neuralgia of Lower Limb: Familiar for a Long Time! - Comment to Ozturk et al., 2021 Pain Practice. 61
33811722 2021
[Varicella-zoster meningoencephalitis and vasculitis after treatment with amenamevir to herpes zoster in the trigeminal nerve area]. 61
33762495 2021
Gabapentin controlled substance status. 61
33674205 2021
[Characteristics of clinical application of electroacupuncture therapy for peripheral neuropathy based on data mining]. 61
33798299 2021
Lumbar Sympathetic Block for Intractable Lower-Limb Postherpetic Neuralgia: Report of Two Cases. 61
33030781 2021
Efficacy and safety of EMA401 in peripheral neuropathic pain: results of two randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. 61
33675631 2021
Should we prescribe anticonvulsants for acute herpes zoster neuralgia and to prevent postherpetic neuralgia?: A protocol for meta-analysis and benefit-risk assessment. 61
33607769 2021
Effect of pain neuroscience education and transcutaneous electrical nerve stimulation on trigeminal postherpetic neuralgia. A case report. 61
33541188 2021
Postlicensure herpes zoster vaccine effectiveness: systematic review protocol. 61
33622942 2021
Comprehensive Review of Topical Analgesics for Chronic Pain. 61
33534003 2021
Structural and functional brain abnormalities in postherpetic neuralgia: A systematic review of neuroimaging studies. 61
33358730 2021
Intravenous lidocaine alleviates postherpetic neuralgia in rats via regulation of neuroinflammation of microglia and astrocytes. 61
33604528 2021
Comparison of therapeutic effects of continuous epidural nerve block combined with drugs on postherpetic neuralgia. 61
32125200 2021
Autologous fat grafting seems to alleviate postherpetic neuralgia - a feasibility study investigating patient-reported levels of pain. 61
32917571 2021
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. 61
33606577 2021
Recombinant Zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure. 61
33580242 2021
A novel method to simultaneously record spinal cord electrophysiology and electroencephalography signals. 61
33617992 2021
Effectiveness and safety of lidocaine patch 5% to treat herpes zoster acute neuralgia and to prevent postherpetic neuralgia. 61
33244838 2021
An update of fire needle acupuncture for acute herpes zoster and prevention of postherpetic neuralgia in adults: A protocol for systematic review and meta-analysis. 61
33429805 2021
Neuropathic Pain: From Mechanisms to Treatment. 61
32584191 2021
Thermographic follow-up of postherpetic neuralgia (PHN) subsequent to Ramsay Hunt syndrome with multicranial nerve (V, VII, VIII and IX) involvement: a case report. 61
33509130 2021
Annual pattern and clinical characteristics of herpes zoster in immunocompetent children in a rural area. 61
33219711 2021
Efficacy of thermotherapy for herpes zoster and postherpetic neuralgia: A protocol for systemic review and meta-analysis. 61
33429743 2021
Mirogabalin-A Novel Selective Ligand for the α2δ Calcium Channel Subunit. 61
33572689 2021
Efficacy of Dorsal Root Ganglion Pulsed Radiofrequency Combined with Paravertebral Injection of Recombinant Human Interferon-α2b in Herpetic Neuralgia. 61
33732017 2021
Application of Nalbuphine in Trigeminal Ganglion Pulse Radiofrequency Surgery in Patients with Postherpetic Neuralgia. 61
33747319 2021
A fixed nitrous oxide/oxygen mixture as an analgesic for patients with postherpetic neuralgia: study protocol for a randomized controlled trial. 61
33407845 2021
Genome-wide association study identifies candidate loci associated with chronic pain and postherpetic neuralgia. 61
33685280 2021
Predicting Postherpetic Neuralgia in Patients with Herpes Zoster by Machine Learning: A Retrospective Study. 61
32915399 2020
Successful Ultrasound-Guided Erector Spinae Plane Block for Herpes Zoster in the Emergency Department: A Case Report. 61
33353812 2020
Transcutaneous electrical nerve stimulation (TENS): a review of applications in dermatology. 61
31418608 2020
Evaluation of Botulinum Toxin Type A Injection in the Treatment of Localized Chronic Pruritus. 61
33488912 2020
Prevalence and Risk Factors of Anxiety and Depression in Patients with Postherpetic Neuralgia: A Retrospective Study. 61
33326962 2020
Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Phosphorylation in Spinal Cords of Mice. 61
33396362 2020
Disrupted default mode network dynamics in recuperative patients of herpes zoster pain. 61
32677342 2020
Evaluation of a Pharmacist Managed Telephone Pain Clinic for Neuropathy Treatment. 61
32924713 2020
Different dosages of valaciclovir for the treatment of herpes zoster in adults: A randomized clinical study. 61
33368338 2020
[Diagnosis, treatment and prophylaxis of herpes zoster]. 61
33141244 2020
Effect of duloxetine premedication for postherpetic neuralgia within 72 h of herpes zoster reactivation [PROCESS]: a study protocol for a randomized controlled trial. 61
33298154 2020
Efficacy of different interventions for the treatment of postherpetic neuralgia: a Bayesian network meta-analysis. 61
33317382 2020
External therapy of Chinese medicine for postherpetic neuralgia: A protocol for systematic review and meta-analysis. 61
33327248 2020
[Zoster disease after Shingrix vaccination]. 61
33294953 2020
Effect of Repeated Paravertebral Injections with Local Anesthetics and Steroids on Prevention of Post-herpetic Neuralgia. 61
33185373 2020
Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach. 61
33238082 2020
Incidence of acute complications of herpes zoster among immunocompetent adults in England: a matched cohort study using routine health data. 61
33216946 2020
Local Administration of Methylcobalamin for Subacute Ophthalmic Herpetic Neuralgia: A Randomized, Phase III Clinical Trial. 61
32372561 2020
Efficacy of Pulsed Radiofrequency in Herpetic Neuralgia: A Meta-Analysis of Randomized Controlled Trials. 61
32701526 2020
Acupuncture therapy for treating postherpetic neuralgia: A protocol for an overview of systematic reviews and meta-analysis. 61
33217857 2020

Variations for Postherpetic Neuralgia

Expression for Postherpetic Neuralgia

Search GEO for disease gene expression data for Postherpetic Neuralgia.

Pathways for Postherpetic Neuralgia

Pathways related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
4 12.24 HLA-DRB1 HLA-B HLA-A
Show member pathways
6 11.72 HLA-B HLA-A
7 11.67 HLA-DRB1 HLA-B HLA-A
8 11.64 HLA-B HLA-A
Show member pathways
11.55 HLA-DRB1 HLA-A
Show member pathways
11.51 HLA-DRB1 HLA-A
11 11.31 HLA-DRB1 HLA-B HLA-A
12 10.97 HLA-DRB1 HLA-B HLA-A
13 10.65 HLA-B HLA-A

GO Terms for Postherpetic Neuralgia

Cellular components related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.65 HLA-DRB1 HLA-B HLA-A
2 Golgi membrane GO:0000139 9.58 HLA-DRB1 HLA-B HLA-A
3 integral component of plasma membrane GO:0005887 9.56 P2RX7 HLA-DRB1 HLA-B HLA-A
4 cell surface GO:0009986 9.54 HLA-DRB1 HLA-B HLA-A
5 early endosome membrane GO:0031901 9.46 HLA-B HLA-A
6 recycling endosome membrane GO:0055038 9.43 HLA-B HLA-A
7 phagocytic vesicle membrane GO:0030670 9.32 HLA-B HLA-A
8 MHC class I protein complex GO:0042612 9.16 HLA-B HLA-A
9 ER to Golgi transport vesicle membrane GO:0012507 9.13 HLA-DRB1 HLA-B HLA-A
10 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.8 HLA-DRB1 HLA-B HLA-A

Biological processes related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.7 HLA-DRB1 HLA-B HLA-A
2 immune response GO:0006955 9.65 HLA-DRB1 HLA-B HLA-A
3 adaptive immune response GO:0002250 9.63 HLA-DRB1 HLA-B HLA-A
4 T cell receptor signaling pathway GO:0050852 9.54 HLA-DRB1 HLA-A
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.51 HLA-B HLA-A
6 type I interferon signaling pathway GO:0060337 9.49 HLA-B HLA-A
7 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.43 HLA-B HLA-A
8 interferon-gamma-mediated signaling pathway GO:0060333 9.43 HLA-DRB1 HLA-B HLA-A
9 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.4 HLA-B HLA-A
10 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.37 HLA-B HLA-A
11 antigen processing and presentation GO:0019882 9.33 HLA-DRB1 HLA-B HLA-A
12 protection from natural killer cell mediated cytotoxicity GO:0042270 9.32 HLA-B HLA-A
13 positive regulation of T cell mediated cytotoxicity GO:0001916 9.13 HLA-DRB1 HLA-B HLA-A
14 detection of bacterium GO:0016045 8.8 HLA-DRB1 HLA-B HLA-A

Molecular functions related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.43 P2RX7 HLA-B HLA-A
2 T cell receptor binding GO:0042608 9.16 HLA-DRB1 HLA-A
3 TAP binding GO:0046977 8.96 HLA-B HLA-A
4 peptide antigen binding GO:0042605 8.8 HLA-DRB1 HLA-B HLA-A

Sources for Postherpetic Neuralgia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....